PH-COVID-Vaccine
IMPORTANT: Monovalent mRNA COVID-19 vaccines are no longer authorized by FDA as 3rd doses for individuals 6 months through 4 (Pfizer) or 5 years (Moderna). This follows the same steps previously taken for COVID-19 booster doses for the 5 years+ population.
- Appointments for monovalent Pfizer-BioNTech or Moderna 3rd doses in people 6 months to 5 years of age and older must be rescheduled until providers have supplies of the bivalent COVID-19 vaccines available.
- Infants (6 months) - Toddlers must register for a vaccination clinic that offers the Pfizer or Moderna vaccine and be accompanied by a parent/legal guardian.
Infant/Toddler Pfizer (6 months – 4 years old):
- 2-dose series (2nd primary dose given 3-8 weeks after first primary dose)
- Bivalent Booster not approved for this age group
Infant/Toddler Moderna (6 months – 5 years old):
- 2-dose series (two primary doses, 4-8 weeks apart).
- Bivalent Booster not approved for this age group - More Pfizer vaccine information
- More Moderna vaccine information
- Children 5 to 11 years old must register for a vaccination clinic that offers the Pfizer vaccine and be accompanied by a parent/legal guardian or present a signed written consent from a parent/legal guardian and be accompanied by an adult.
- Children 6 to 11 years old must register for a vaccination clinic that offers the Moderna vaccine and be accompanied by a parent/legal guardian or present a signed written consent from a parent/legal guardian and be accompanied by an adult.
Download Minor Consent Form Here Descargue El Formulario De Consentimiento Del Menor Aquí
Pediatric Pfizer (5 – 11 years old):
- 2-dose series (second primary dose given -8 weeks after first primary dose).
- For Moderately or Severely Immunocompromised individuals, a 3rd dose can be administered 4 weeks after receiving 2nd dose.
- Bivalent Booster dose is recommended 2 months after last primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.
Pediatric Moderna (6 – 11 years old):
- 2-dose series (second primary dose given 4-8 weeks after first primary dose).
- For Moderately or Severely Immunocompromised individuals, a 3rd dose can be administered 4 weeks after receiving 2nd dose.
- Bivalent Booster dose is recommended 2 months after last primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.
- Additional eligibility information
- Additional Pfizer information
- Additional Moderna information
- Teenagers 12 to 17 years old must register for a vaccination clinic that offers the Pfizer, Moderna or Novavax vaccine and be accompanied by a parent/legal guardian or present a signed written consent from a parent/legal guardian and be accompanied by an adult.
Download Minor Consent Form Here Pfizer:
Descargue El Formulario De Consentimiento Del Menor Aquí*If scheduling for Novavax, please still complete the Minor Consent Form*
- 2-dose series (second primary dose given 3-8 weeks after first primary dose).
- For Moderately or Severely Immunocompromised individuals, a 3rd dose can be administered 4 weeks after receiving 2nd dose
- Bivalent Booster dose is recommended 2 months after last primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.
Moderna:
- 2-dose series (second primary dose given 4-8 weeks after first primary dose).
- For Moderately or Severely Immunocompromised individuals, a 3rd dose can be administered 4 weeks after receiving 2nd dose
- Bivalent Booster dose is recommended 2 months after last primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.
Novavax:
- 2-dose series (second primary dose given 3-8 weeks after first primary dose).
- Bivalent Booster dose is recommended 2 months after 2nd primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.
Monovalent mRNA COVID-19 vaccines are no longer authorized by FDA as booster doses for individuals 12 years of age and older
- More information on monovalent/bivalent COVID-19 vaccine booster
- Johnson & Johnson vaccines can only be given to individuals age 18 years and older.
- Additional eligibility information
- Booster dose information
- More information on Novavax
-
- Individuals 18 and older may register for a vaccination clinic that offers any of the available vaccines: Pfizer, Moderna, Johnson & Johnson, or Novavax
Pfizer:
- 2-dose series (second primary dose given 3-8 weeks after first primary dose).
- For Moderately or Severely Immunocompromised individuals, a 3rd dose can be administered 4 weeks after receiving 2nd dose
- Bivalent Booster dose is recommended 2 months after last primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.Moderna:
- 2-dose series (second primary dose given 4-8 weeks after first primary dose).
- For Moderately or Severely Immunocompromised individuals, a 3rd dose can be administered 4 weeks after receiving 2nd dose
- Bivalent Booster dose is recommended 2 months after last primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.Novavax:
- 2-dose series (second primary dose given 3-8 weeks after first primary dose).
- Bivalent Booster dose is recommended 2 months after 2nd primary dose.
- For people who previously received a monovalent booster dose(s), the bivalent booster is administered at least 2 months after the last monovalent booster dose.Johnson & Johnson:
- 1-dose series (a booster dose given at least 2 months after the first primary dose. A 2nd booster dose given at least 4 months after the 1st booster has been received)Monovalent mRNA COVID-19 vaccines are no longer authorized by FDA as booster doses for individuals 12 years of age and older.
- More information on monovalent/bivalent COVID-19 vaccine booster
- 6 months - 4 years
- Regardless of Immune Response:
- No recommendation for any booster or additional doses at this time.
- Regular Immunity:
- Should receive the Updated Booster (bivalent) dose of Pfizer at least two months after receiving their last dose, regardless of type (primary series or booster). - Compromised Immunity:
- Should receive an additional (monovalent) dose of Pfizer at least four weeks after receiving the second dose in their primary series.
- Should receive the Updated Booster (bivalent) dose of Pfizer at least two months after receiving their last dose, regardless of type (primary series or booster).
- Regular Immunity:
- Should receive the Updated Booster (bivalent) dose at least two months after receiving their last dose, regardless of type (primary series or booster). - Compromised Immunity:
- Should receive an additional (monovalent) dose of Pfizer at least four weeks after receiving the second dose of their primary series.
- Should receive the Updated Booster (bivalent) dose at least two months after receiving their last dose, regardless of type (primary series or booster).
- Regardless of Immune Response:
- 6 months - 4 years
- Regardless of Immune Response:
- No recommendation for any booster or additional doses at this time.
- Regular Immunity:
- Should receive the Updated Booster (bivalent) dose of Pfizer at least two months after receiving their second dose. - Compromised Immunity:
- Should receive an additional (monovalent) dose of Moderna at least four weeks after receiving the second dose in their primary series.
- Should receive the Updated Booster (bivalent) dose of Pfizer at least two months after receiving their additional/third dose of the primary series.
- Regular Immunity:
- Should receive the Updated Booster (bivalent) dose at least two months after receiving their last dose, regardless of type (primary series or booster). - Compromised Immunity:
- Should receive an additional (monovalent) dose of Moderna at least four weeks after receiving the second dose of their primary series.
- Should receive the Updated Booster (bivalent) dose at least two months after receiving their last dose, regardless of type (primary series or booster).
- Regardless of Immune Response:
- 12 years+
- Regardless of Immune Response:
- Should receive the Updated Booster (bivalent) dose at least two months after their last dose, regardless of type (primary series or booster).
- Regardless of Immune Response:
- Should receive the Updated Booster (bivalent) dose at least two months after their last dose, regardless of type (primary series or booster).
- In some limited situations, may receive the Novavax booster dose at least six months after completion of their primary series. Only for people for whom an mRNA Updated Booster is not accessible or clinically appropriate, or who would otherwise not receive a booster dose.
- Regardless of Immune Response:
- 18 years+
- Regular Immunity:
- Should receive the Updated Booster (bivalent) dose at least two months after their last dose, regardless of type (primary series or booster).
- In some limited situations, may receive the J&J booster dose at least two months after completion of their first dose. Only for people for whom an mRNA Updated Booster is not accessible or clinically appropriate, or who would otherwise not receive a booster dose. - Compromised Immunity:
- Should receive an additional (monovalent) dose of an mRNA vaccine at least four weeks after receiving the first dose of their primary series.
- Should receive the Updated Booster (bivalent) dose at least two months after receiving their last dose, regardless of type (primary series or booster).
- Regular Immunity:
The CDC recommends a third vaccine dose for certain groups of people with weakened immune systems who received either the Pfizer-BioNTech or Moderna COVID-19 vaccine. Some examples include:
- Receiving active cancer treatment for tumors or cancers of the blood
- Received an organ transplant and are taking medicine to suppress the immune system
- Received a stem cell transplant within the last 2 years or are taking medicine to suppress the immune system
- Moderate or severe primary immunodeficiency
- Advanced or untreated HIV infection
- Active treatment with high-dose corticosteroids or other drugs that may suppress your immune response
Please talk to your healthcare provider about your medical condition, and whether getting an additional dose is appropriate for you.
Riverside County Vaccination Clinics
Riverside County Public Health and our Partner sites offer vaccination clinics throughout the County.
Vaccine Safety & Information
Find out more information about the vaccines.
COMMUNITY PROVIDERS OFFERING VACCINATION CLINICS
Community Providers
Vaccination is offered by a variety of community healthcare partners. Please confirm with the Clinic which vaccine is available as some have Moderna vaccine and some offer the Pfizer vaccine. All vaccinations are by appointment only. Please be advised that Public Health is unable to provide information on appointment availability.
What You Need to Know
A safe and effective COVID-19 vaccine will be one of the most important tools to end the COVID-19 pandemic. California is planning to distribute and administer vaccines as quickly as possible.
This will be done only after a vaccine's safety has been reviewed and approved by top health experts. Initial vaccine supply will be limited, and California is making sure that these first vaccines are distributed and administered equitably. The first vaccines will be provided to healthcare workers and residents of long-term care facilities.
It will take some time before the vaccine is available to everyone, and while experts learn more about the protection vaccines provide, it's important to keep using all the tools available to us to help stop the pandemic. This includes wearing masks, washing hands, staying 6 feet apart.
At first, the limited supplies of vaccines will go to frontline healthcare workers and residents of long-term care facilities. As the supply of vaccine increases, those with the highest risk of becoming infected and spreading COVID-19 will receive vaccines.
For questions about the COVID-19 vaccine, visit https://covid19.ca.gov/vaccines. You may also call 951-358-5000, Monday – Friday 8 am – 5 pm or email: rivco.vaccines@ruhealth.org.
Riverside County Vaccination Data
Current data on vaccine coverage for communities and population groups within Riverside County.
FAQ's
It is possible to have an allergic reaction to any vaccine or medication including the COVID-19 vaccine. Serious allergic reactions from the COVID-19 vaccine are very rare but talk to your doctor before getting your vaccine if you have a history of severe allergic reactions.
Vaccination against COVID-19 will help to reduce the number of people sick with COVID-19, and it could help reduce the severity of illness even if people still get sick. Vaccination against COVID-19 will also help to reduce hospitalizations and death from the virus. If enough people become vaccinated against COVID-19, it will make it easier and safer for businesses and schools to stay open.
No, none of the vaccines that have been released or that are in development contain the virus that causes COVID-19. Many vaccines can cause a mild fever, tiredness and body or muscle aches but this is not the same as getting the virus. These symptoms are a sign that the vaccine has caused the immune response important for protection against disease.
The Pfizer and Moderna vaccines require 2 shots several weeks apart, while the Johnson and Johnson vaccine is a single-dose vaccine.
No, the main tests used for determining if a person is currently infected like the nose or mouth swab test will not become positive if you get the vaccine. A vaccinated person might test positive for antibodies. When antibodies to COVID-19 are found, it’s a sign that your body’s immune response to the vaccine worked and that you may have protection against COVID-19.
Yes. Until we know more about the level of protection from vaccines in real-world situations, facial coverings and social distancing will continue to be very important to prevent spread of the virus. Also, while the two current vaccines are very effective, no vaccine can protect 100% of people. Some people who get the vaccine will not generate an immune response so it will be important to continue wearing a face covering and practicing social distancing until we reach herd immunity from widespread vaccination.
No, the vaccines should be covered by public and private health insurance. For people without health insurance there will be no cost for the COVID-19 vaccine.
Most importantly, cover your face and mouth with a face covering whenever you’re around other people. This helps prevent the spread of the virus that causes COVID-19. Always practice social distancing by keeping at least six feet from others when not in your own home and avoid people who are sick if you can. It’s also important to wash your hands frequently, particularly when you’re returning home after being out for essential activities like grocery shopping.
Yes! Both COVID-19 and the virus that causes flu will be spreading this winter. The Flu shot only protects you from the flu but it’s important to get your vaccine to avoid getting both COVID-19 and flu at the same time. Also, protecting against flu will help keep our hospitals more open to help people with COVID-19 as it spreads through the winter. The flu vaccine and COVID-19 vaccine may have to be given a few weeks apart so talk to your doctor about the timing of your flu vaccine.
On April 23, a CDC panel recommended that the pause in the use of the Johnson & Johnson vaccine be lifted. The panel also recommended that a warning label be added to the vaccine packaging noting the very rare blood clotting disorder risk. Based on the panel’s recommendation, the FDA ended the pause; states and local jurisdictions can now resume use of the J&J vaccine.
The CDC and FDA will provide monitoring and treatment information to health care providers and vaccine recipients.
Added April 24, 2021
The identification of what is approximately a less than 2-in-a-million risk associated with the Johnson & Johnson vaccine is a sign that the nation’s safety monitoring system for COVID vaccines is working. After any vaccine is successful in clinical trials and approved for use, the FDA continues to monitor it for safety. The pause in the use of the J&J vaccine allowed scientists to evaluate each incidence of the clotting disorder. They determined that the level of risk was very low and that the benefits of continued use of the J&J vaccine greatly outweighed any risk associated with it.
Added April 24, 2021
The 10-day pause gave health officials time to review additional data to better understand the degree of risk associated with the Johnson & Johnson vaccine related to a blood clotting disorder. It also gave federal agencies and the medical community time to determine and share information on the most appropriate treatment response. During that time, nine additional cases of the clotting disorder were identified, bringing the total number of known cases to 15 (among the nearly 7 million people who received the vaccine).
The decision to lift the pause is based on the experts’ determination that the benefits of again administering the vaccine greatly outweigh the very small degree of risk associated with its use, particularly now that the risk and treatment protocols are better understood. The risk of blood clotting is much higher for people who contract COVID than it is for people who receive the J&J vaccine.
Added April 24, 2021
The likelihood of the blood clotting disorder resulting from the Johnson & Johnson vaccine is extremely rare. The risk varies by age and gender. There have been fewer than 1 case per million for men and for women who are 50 years or older; the risk is estimated to be about 7 cases per million for women age 18 to 49. If you have questions about the J&J vaccine or other vaccines, talk to your doctor.
ENROLL TO BECOME A COVID-19 VACCINE PROVIDER
Vaccine Program Enrollment
Hospitals, pharmacies, clinics, and other healthcare providers interested in administering COVID-19 vaccine must be enrolled in the federal COVID-19 Vaccination Program. Vaccines and ancillary supplies will be procured and distributed by the federal government at no cost to enrolled, approved COVID-19 vaccination providers.